nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2006 | Original Research Article

The Role of Antimalarials in the Exacerbation of Psoriasis

A Systematic Review

verfasst von: Dr Sari M. Herman, Michael H. Shin, Anne Holbrook, Donald Rosenthal

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective: To critically review the body of literature that refutes or supports the role of antimalarials in the exacerbation of psoriasis.

Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were reviewed to identify English-language publications from 1966–2005 examining the role of antimalarials in the exacerbation of psoriasis. A total of 374 articles were identified, of which 32 studies met the inclusion criteria. All available clinical trials or reported cases of the use of antimalarials for patients with psoriasis were included. Data from clinical studies were summarized according to the level of evidence and the outcome of the study. Data were entered into a standardized data extraction form by two independent reviewers.

Results and conclusion: No randomized trial evidence was found. Only one cohort study was available for review. A total of 31 case series and case reports were obtained. There is no strong evidence to refute or support the role of antimalarials in the exacerbation of psoriasis. Controlled trials of antimalarial therapy and its effect on psoriasis are warranted.

Lebwohl M. Psoriasis. Lancet. 2003; 361: 1197–204PubMedCrossRef

Veale DJ, FitzGerald O. Psoriatic arthritis-pathogenesis and epidemiology. Clin Exp Rheumatol. 2002; 20 (6 Suppl. 28): S27–33PubMed

Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996; 35: 1289–91PubMedCrossRef

Habif TP. Clinical dermatology [e-book; online]. Philadelphia (PA): Mosby, 2004. Available from URL: http://www.mdeonsult.com/ [Accessed 2005 May 30]

Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141: 185–91PubMedCrossRef

Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978; 157: 238–44PubMedCrossRef

Abel E, Di Cicco L, Orenberg E, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol. 1986; 15: 1007–22PubMedCrossRef

Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol. 1998; 16: 333–51PubMedCrossRef

Tsankov N, Angelova I, Kazandijieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol. 2000; 1: 159–65PubMedCrossRef

10.

Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg. 2002; 6: 2–7PubMedCrossRef

11.

Olsen TG. Chloroquine and psoriasis. Ann Intern Med. 1981; 94: 546–7PubMed

12.

Vestey FP, Savin FA. Psoriasis worsened by antimalarial prophylaxis. J Infect. 1992; 24: 211–21PubMedCrossRef

13.

Brenner S, Cabili S, Wolf R. Widespread erythematous scaly plaques in an adult. Arch Dermatol. 1993; 129: 1331–5PubMedCrossRef

14.

MacKenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine. Clin Rheum Dis. 1980; 7: 545–66

15.

Mallett R, Pye R. Risks and benefits of prophylactic antimalarial drugs [letter]. BMJ. 1989; 299: 1400PubMedCrossRef

16.

Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992; 19: 1724–6PubMed

17.

Kuflik EG. Effect of antimalarial drugs on psoriasis. Cutis. 1980; 26: 153–6PubMed

18.

Cornbleet T. Preliminary and short report: action of synthetic antimalarial drugs on psoriasis. J Invest Dermatol. 1956; 26: 435–6PubMedCrossRef

19.

Luzar MJ. Hydroxychloroquine in psoriatic arthropathy. J Rheumatol. 1982; 9: 462–4PubMed

20.

Slagel GA, James WD. Plaquenil induced erythroderma. J Am Acad Dermatol. 1985; 12: 857–62PubMedCrossRef

21.

Knudsen EA. Exfoliative erythroderma due to chloroquine: psoriasis [abstract]. Acta Derm Venereol (Stockh). 1962; 42: 344

22.

Graniner LW. Exfoliative dermatitis as a complication of chloroquine (Aralen) therapy in rheumatoid arthritis. AMA Arch Derm. 1958; 77: 722–4CrossRef

23.

Reed WB, Becker SW. Psoriasis and arthritis. Arch Dermatol. 1960; 81: 577–85PubMedCrossRef

24.

Witten VH, Sulzberger MB. Psoriasis: an interesting and perhaps distinctive response following quinacrine therapy. Arch Dermatol. 1956; 73: 636CrossRef

25.

Witten VH, Sultzberger MC. Psoriasis: an unusual response following atabrine. Arch Dermatol. 1956; 74: 210–1

26.

Kammer GM, Solar NA, Gibson DJ. Psoriatic arthritis: a clinical, immunologic, and HLA study of 100 patients. Semin Arthritis Rheum. 1979; 9: 75–95PubMedCrossRef

27.

Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum. 1990; 33: 1449–61PubMedCrossRef

28.

Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics. 2001; 19: 715–28PubMedCrossRef

29.

Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989; 95 Suppl. 2: 2S–4SPubMed

30.

Baker H. The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagicum. Br J Dermatol. 1966; 78: 161–6CrossRef

31.

Bielicky T. Light-sensitive psoriasis and antimalarial drugs. J Invest Dermatol. 1963; 41: 1–2PubMed

32.

Bielicky T, Malina L, Sonka J. Glucose metabolism and clinical alterations in psoriasis under chloroquine therapy. Acta Derm Venereol (Stockh). 1966; 46: 72–7

33.

Cormia FE, Noun MH. Treatment of pustular psoriasis and pustular bacterid with quinacrine (Atabrine). AMA Arch Derm Syphilol. 1953; 68: 337–8PubMedCrossRef

34.

Friedman SS. Pustular psoriasis associated with hydroxy chloroquine. J Am Acad Dermatol. 1987; 16: 1256–7PubMedCrossRef

35.

Gordon MM, Sturrock RD. Antimalarials in the management of psoriatic arthritis? [letter]. Clin Exp Rheumatol. 2002; 20: 117PubMed

36.

Gray RG. Hydroxychloroquine provocation of psoriasis [letter]. J Rheumatol. 1985; 12: 391PubMed

37.

Harwell WB. Quinidine-induced psoriasis [letter]. J Am Acad Dermatol. 1983; 9: 278PubMedCrossRef

38.

Hays S, Camisa C, Luzar MJ. The coexistence of systemic lupus erythematous and psoriasis. J Am Acad Dermatol. 1984; 10: 619–22PubMedCrossRef

39.

Katugampola G, Katugampola S. Chloroquine and psoriasis. Int J Dermatol. 1990; 29: 153–4PubMedCrossRef

40.

Kirschenbaum MC. Psoriasis following administration of antimalarial drugs. JAMA. 1963; 185: 1044PubMedCrossRef

41.

Luzar MJ, Camisa C. Antimalarials in psoriatic arthritis [letter]. J Rheumatol. 1983; 10: 833–4

42.

O’Quinn S, Kennedy CB, Naylor LZ. Psoriasis, ultraviolet, and chloroquine. Arch Dermatol. 1964; 90: 211–6PubMedCrossRef

43.

Potasman I, Seligmann H. A unique case of mefloquine-induced psoriasis [letter]. J Travel Med. 1998; 5: 156PubMedCrossRef

44.

Reed WB. Psoriatic arthritis: a complete clinical study of 86 patients. Acta Derm Venereol (Stockh). 1961; 41: 396–403

45.

Roberts MET, Wright V, Hill AGS, et al. Psoriatic arthritis. Ann Rheum Dis. 1976; 35: 203–12CrossRef

46.

Sayers ME. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med. 1992; 93: 474–5PubMedCrossRef

47.

Tmavsky K, Zbojanova M, Vlcek F. Antimalarials in psoriatic arthritis [letter]. J Rheumatol. 1983; 10: 833–4

48.

Levine M, Haslam D, Walter S, et al. Harm. In: Guyatt G, Rennie D, editors. Users’ guide to the medical literature. Chicago: American Medical Association, 2002: 121–153

49.

Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol. 1992; 11: 269–74PubMed

Titel: The Role of Antimalarials in the Exacerbation of Psoriasis
A Systematic Review
verfasst von: Dr Sari M. Herman
Michael H. Shin
Anne Holbrook
Donald Rosenthal
Publikationsdatum: 01.08.2006
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 4/2006
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200607040-00006

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

The Role of Antimalarials in the Exacerbation of Psoriasis

A Systematic Review

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Update Dermatologie

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

A Comprehensive Review of the Long-Term and Short-Term Treatment of Melasma with a Triple Combination Cream

Pharmionics in Dermatology

Single-Day Therapy for Recurrent Genital Herpes

Increased Hair Shedding May be Associated with the Presence of Pityrosporum ovale

Nephrogenic Fibrosing Dermopathy

Cutaneous Metastasis of Renal Cell Carcinoma

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Update Dermatologie